Karachi: IBL HealthCare Limited has released its financial results for the fiscal year ending in 2026, highlighting a net revenue increase alongside a strategic shift in its business portfolio. The company reported a net revenue of 4.61 billion PKR, marking a 7% rise compared to the previous fiscal year. This growth comes as the company navigates the financial implications of exiting certain discontinued portfolios.

The company witnessed a notable improvement in its gross profit, which reached 1.64 billion PKR, reflecting a 14% increase. Consequently, the gross margin improved to 35.7% from 33.5% in FY2025. Profit before tax also experienced a moderate move upward, registering a total of 401.3 million PKR, amounting to a 6% increase from the prior year.

According to information available from the Pakistan Stock Exchange (PSX), the fiscal year 2026 saw IBL HealthCare Limited’s profit after tax stabilize at 220.4 million PKR, sustaining a growth of 6% compared to the previous year. The company’s earnings per share stood at 2.24 PKR, a slight increase from 2.11 PKR in FY2025.

The company's major product lines—Nutrition, Sweetener and Beverages, and Medical and Surgical Disposables—contributed differently to the revenue stream. Nutrition products saw a modest increase from 1,655 million PKR in FY2025 to 1,696 million PKR in FY2026. Sweetener and Beverages experienced a slight decline, generating 605 million PKR compared to 621 million PKR in the previous year. Meanwhile, the Medical and Surgical Disposables line saw an increase from 2,046 million PKR to 2,306 million PKR.

Total assets reported for FY2026 were 4.03 billion PKR, with total equity reaching 2.54 billion PKR. The company’s leadership emphasized that the headline growth primarily reflects the performance of its continuing business, underscoring the strategic importance of its remaining product lines in driving future growth.